Press coverage about Cellectis (NASDAQ:CLLS) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.8119212342817 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Cellectis (NASDAQ CLLS) opened at $29.48 on Friday. The firm has a market capitalization of $1,059.16, a price-to-earnings ratio of -12.23 and a beta of 2.12. Cellectis has a one year low of $17.29 and a one year high of $35.07.
Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, November 13th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.16). Cellectis had a negative net margin of 217.25% and a negative return on equity of 30.66%. sell-side analysts anticipate that Cellectis will post -2.89 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Cellectis (CLLS) Earning Somewhat Favorable Press Coverage, Study Finds” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2018/01/21/cellectis-clls-earning-somewhat-favorable-press-coverage-study-finds.html.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.